Company intelligence / Profile preview

Asterias Biotherapeutics

Menlo Park, California, United Statesannualreports.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Asterias was conducting Phase 1/2a clinical trials for AST-OPC1 in spinal cord injury and VAC2 in non-small cell lung cancer. The company merged with BioTime in a transaction that was expected to be completed in Q1 2019.

Therapeutic areas: CardiovascularMetabolic DisordersRheumatologyOphthalmologyHematologyOncologyNeurology
Modalities: Cell therapyStem cell therapyImmunotherapyPluripotent stem cells
Industry: Biotech

Drug pipeline

3 assets

OPC1

Phase 2

Indications: Spinal cord injury

2 more assets in the full pipeline.

Request access →

Partnerships

California Institute for Regenerative Medicine (CIRM)Cancer Research UKWuchan Zhongda Geron

Beyond the preview

Go deeper on Asterias Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asterias Biotherapeutics.

Explore the full profile